bgb-43395

Resumen de Ensayos Clínicos

2 ensayos encontrados
Sobre bgb-43395

Se está recopilando información detallada sobre este medicamento.

Categoría Otros Medicamentos
2
Total Ensayos
1
Reclutando
1
Activo
0
Completado
502
Inscripción Total
11
Países
Centros activos para bgb-43395
Centros reclutando 11 países
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283 Fase 1 Reclutando 399 pacientes
Inicio: Dec 2023
Fin: Nov 2028
Intervencional
Medicamentos: BGB-43395 Elacestrant Fulvestrant Letrozole
This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone ...
United States, Australia, Brazil, China, France, Japan, Malaysia, Moldova, New Zealand, South Korea,
Ver Detalles ClinicalTrials.gov ¿Soy elegible?
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT06257264 Fase 1 Activo 103 pacientes
Inicio: Mar 2024
Fin: Aug 2026
Intervencional
Medicamentos: BG-68501 BGB-43395 Fulvestrant
This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-68501 in partici...
United States, Australia, China, Israel, Moldova, New Zealand
Ver Detalles ClinicalTrials.gov ¿Soy elegible?
Volver al Glosario Ver Todos los Ensayos Filtrar Reclutando